Belluscura plc
("Belluscura" or the "Company")
Belluscura Launches Direct to Consumer Sales and Rental Program
.
LONDON, U.K., PLANO, TX, U.S. and SHENZHEN, CHINA (24 October 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that early results on the two-month-old direct to consumer program have exceeded the Board's initial expectations.
The Company has introduced a three-prong direct sales, leasing and short-term rental program for its established X-PLOR® device that has been well received by customers. Recognising a significant need and opportunity to provide portable oxygen concentrators to customers not previously served by durable medical equipment companies, the Company designed a program intended to capture a meaningful underserved population of people suffering from lung disease.
The Company sees this program expanding significantly with the launch of the DISCOV-R™ portable oxygen concentrator.
Bob Fary, Senior Vice President Sales and Marketing Belluscura plc, commented:
"I am very excited about the new direct-to consumer sales program. We have identified a potentially significant sales opportunity that not only benefits the Company, but underrepresented patients as well."
For further information please contact:
| Belluscura plc | Tel: +44 (0)20 3128 8100 |
| Adam Reynolds, Chairman Simon Neicheril, Chief Financial Officer | |
| | |
| | |
| SPARK Advisory Partners Limited Nominated Adviser | Tel: +44 (0)20 3368 3550 |
| Neil Baldwin / Jade Bayat | |
| | |
| | |
| Dowgate Capital Limited Broker | Tel: +44 (0)20 3903 7715 |
| Russell Cook / Nicholas Chambers | |
| | |
| | |
| MHP Financial PR & Investor Relations | Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com |
| Katie Hunt/Matthew Taylor | |
About Belluscura plc (www.Belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
